Share This Page
Drugs in MeSH Category Hemostatics
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | DIAPID | lypressin | SOLUTION;NASAL | 016755-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Hemostatics (NLM MeSH Class): Key Exclusivity Timelines, Patent Estates, and Generic/Biosimilar Risk
Hemostatics span prescription drugs, biologics, and combination products used to control bleeding across surgery, trauma, and chronic bleeding disorders. The patent landscape is shaped by (1) formulation and device-like compositions (oxidized/reducing polysaccharides, thrombin/antifibrinolytics, hemostatic matrices), (2) method-of-use claims (surgical field, wound bed, route, timing), and (3) biologic manufacturing and patient-identification claims for certain plasma-derived or recombinant products. Commercially, the market is pulled by hospital purchasing cycles, reimbursement coverage, limited class switching, and increasing use of minimally invasive surgery where fast-acting hemostats and adjuncts win.
Below is the structured market-and-IP view for NLM MeSH “Hemostatics,” focusing on exclusivity timing, major patent estate patterns, and the generic entry risk that drives settlement and licensing behavior.
What is the patent estate structure for hemostatics in MeSH Class Hemostatics?
Answer: Hemostatics patents cluster around composition (active ingredient plus stabilizers/absorbents), method of use (application to wound bed/surgical field, timing, re-application), and product-specific performance (clot strength, absorbability, dwell time). For biologic and plasma-derived hemostats, manufacturing and purification process claims and safety/characterization claims narrow true generic substitution.
Composition-centric claim patterns
Common claim strategies in hemostatics include:
- Thrombin and fibrin-based systems: claims cover thrombin composition, concentration ranges, stabilizers (calcium, buffers), cofactor pairing, and delivery format (matrix, spray, patch).
- Oxidized/reduced polysaccharides: claim around degree of oxidation, molecular weight distribution, and sustained moisture retention in the wound environment.
- Collagen-based products: claim around collagen source and crosslinking, particle size distribution, and surface treatment for hemostatic acceleration.
- Antifibrinolytics + topical adjuncts: claim around drug release profile and combination dosing.
Method-of-use and surgical workflow claims
Method patents often include:
- “Apply to bleeding surface” language with timing and repeat application constraints.
- Route-specific restrictions (topical, intranasal, intraoperative application).
- Indication-limited use (orthopedic, hepatic, dental, neurosurgery, trauma).
Manufacturing-process and characterization claims
For biologics and plasma-derived products:
- purification steps (fractionation, viral inactivation, chromatography conditions),
- stability specs and quality attributes tied to potency,
- assays and acceptance criteria.
These claims reduce the practical interchangeability of “same active ingredient” products even when nonclinical comparability is strong.
Which hemostatics have the strongest exclusivity and why (formulations, devices, and biologics)?
Answer: Exclusivity is strongest where patents protect both the core active system and the delivery format, or where regulatory pathway hinges on biologic comparability. Products with multiple overlapping composition and method-of-use families typically maintain a “patent thicket,” delaying generic entry despite earlier active-ingredient visibility.
High-protection categories
- Fibrin sealants / thrombin-based combinations
- Multiple families: protein composition, fibrinogen/thrombin ratio, calcium dependence, crosslinking kinetics, drying/spray parameters, and surgical performance claims.
- Oxidized polysaccharide matrices
- Claims target polymer chemistry, oxidation level, and wound-surface dwell mechanics.
- Recombinant or plasma-derived proteins
- Process patents and product characterization claims can extend effective exclusivity beyond the last listed “composition” patent.
When does hemostatic drug exclusivity expire and what drives the “effective launch window”?
Answer: Effective exclusivity is usually set by the last expiring enforceable patent family covering the delivered product plus the related method-of-use. “Effective launch” is often later than the earliest expiration date because:
- patent families overlap by formulation and use,
- amendments and continuation practice extend terms,
- settlement agreements delay launch, especially after Paragraph IV litigation.
Key timing mechanics in hemostatics
- Orange Book-listed small molecules/topicals: generic entry is tied to last listed patent expiry or litigation-stayed approval.
- Biologics: exclusivity is tied to licensure exclusivity and biosimilar development and interchangeability frameworks; “same drug” substitution is not equivalent to small-molecule generic timing.
Settlement-driven delays
Hemostatics commonly exhibit settlement outcomes in which:
- the first generic/biosimilar agrees to a later launch date,
- carve-outs apply (non-overlapping indications, different delivery formats, or restricted patient populations).
What patents protect topical hemostats (oxidized cellulose, gelatin, collagen) versus systemic hemostats?
Answer: Topical hemostats are dominated by formulation, chemistry of the absorbent/hemostatic matrix, and application method claims. Systemic hemostats (where applicable within the MeSH breadth) rely more on dosing, indication, and route-of-administration patents.
Topical: oxidized/reduced polysaccharides, gelatin, collagen
Typical protected elements:
- composition ratios (gelatin concentration, collagen density, binding matrix),
- particle size and surface treatment,
- rehydration or moisture retention parameters,
- dwell time and “do not disturb” workflow constraints,
- shelf stability and sterilization methods.
Systemic: antifibrinolytics and clotting factor supports
Typical protected elements:
- dosing regimen and pharmacokinetics-driven schedules,
- patient selection and indication,
- combination protocols with other agents.
How many patents cover blockbuster hemostats and what is the typical “patent thicket” depth?
Answer: For leading hemostatic brands, the patent estate commonly includes multiple overlapping families: composition/formulation, manufacturing, method-of-use, and sometimes packaging or administration devices. The count can reach double digits across related SKUs, with the strongest estates showing:
- long continuations,
- claim coverage on both “how” and “what” is applied,
- and additional process patents that are hard to design around.
Patent-family architecture that extends exclusivity
- Earliest filing in composition and formulation
- Continuations expanding ranges and dependent claims for:
- concentration,
- activation state,
- ratio of components,
- delivery format.
Which companies challenge hemostatic patents via Paragraph IV and what do settlements usually look like?
Answer: Patent challenges in hemostatics follow the same playbook as other branded products: generic applicants file Paragraph IV certifications for Orange Book-listed patents, then negotiate settlements that delay launch or narrow the claim overlap. The most common settlement shapes for hemostatics are:
- deferred launch date,
- limitation to non-overlapping indications or delivery formats,
- and patent licensing for entry.
Practical litigation drivers
- Claim validity and non-infringement turn on “sameness” of composition parameters and delivery mechanics.
- Even small changes in polymer chemistry, thrombin stabilization, or matrix architecture can become central to infringement theories.
What is the Orange Book status of hemostatics and how does that determine generic entry risk?
Answer: Orange Book status is the gating item for small-molecule generics. If a product has multiple Orange Book-listed patents with enforceability windows extending into later years, the generic entry risk is higher and settlement becomes more likely.
Orange Book risk checklist (small molecules/topicals)
- number of listed patents per NDA/ANDA,
- type: drug substance, drug product formulation, method-of-use,
- whether the patents are expiring singly or in clusters,
- and whether litigation exists or has ended.
How does biosimilar risk apply to hemostatics (plasma-derived and recombinant products)?
Answer: Biosimilar risk exists for biologic hemostats, but substitution timing and claims strategy are different from small-molecule generics. Biosimilar developers face:
- scientific comparability and manufacturing control,
- patent estates covering manufacturing and characterization,
- and possible method-of-use patent coverage tied to clinical handling.
Biosimilar “design-around” constraints
For biologics, “design-around” is constrained because the biological product must meet tight similarity criteria. That shifts risk from purely chemical compositional changes to process and regulatory comparability.
What formulations are protected by hemostatic patent estates (thrombin concentration, fibrinogen ratios, oxidized polymer chemistry)?
Answer: Hemostatic formulation patents typically protect:
- concentration ranges (thrombin, fibrinogen, antifibrinolytics),
- ratios between components (fibrin system stoichiometry),
- and physicochemical properties tied to performance (absorbability, clot strength, dwell time).
Formulation parameters that repeatedly appear in patent claims
- protein concentration and buffer composition,
- calcium dependence,
- activation conditions,
- polymer oxidation level and molecular weight distribution,
- matrix porosity and rehydration profile,
- sterilization conditions affecting potency and stability.
What method-of-use patents restrict hemostat application (timing, surgical setting, re-application)?
Answer: Method-of-use claims frequently restrict:
- the procedural context (surgical field category),
- dwell/time constraints,
- and handling instructions (whether to leave in place, whether to remove or re-apply).
Typical claim limits
- “Apply to bleeding surface and allow to remain undisturbed for X minutes”
- “Administer at the wound bed during Y surgical step”
- “Repeat application if bleeding persists under defined criteria”
These constraints matter for both infringement analysis and product positioning for payers.
What patent litigation affects hemostatics right now (and why timing matters for launches)?
Answer: Litigation affects launch timing through automatic stays on FDA approval for Paragraph IV challenges and through negotiated settlement triggers. In hemostatics, infringement often hinges on formulation parameter differences and administration method claims, so early court outcomes do not always translate into easy entry.
Litigation-driven “design-around” pattern
Generic entrants often:
- alter delivery format,
- adjust concentration targets within safe performance boundaries,
- and change application workflow instructions to reduce method-of-use overlap.
Whether that avoids infringement depends on the claim construction adopted in litigation.
How do hemostatics compare with adjacent coagulation competitors in patent strength and launch timing?
Answer: Compared with broad anticoagulant or hematology drug classes, hemostatics show higher fragmentation in “how the product is used,” with delivery systems and workflow claims that increase entry friction. Patent strength is usually highest for brands that combine:
- a biologic or protein active core,
- with a specific delivery format and use claims.
Competitive set dynamics
- Topical hemostats compete on “time-to-hemostasis” and ease-of-use more than purely on active ingredient.
- That creates commercial pressure to keep the delivery format protected by patent families, delaying “true replacements.”
What generic entry risks exist for hemostatics when patent coverage is focused on method-of-use?
Answer: Method-of-use-focused estates elevate entry risk even when formulation can be matched, because the developer must ensure that marketing, instructions for use, and actual administration patterns do not infringe. Risk is heightened when:
- the method-of-use claim includes procedural steps tied to labeled instructions,
- and the competitor’s IFU aligns closely with the branded workflow.
How risk is managed
- Label carve-outs and IFU redesign
- Narrower indication targeting
- Settlement with licensing for labeled overlaps
Commercial market dynamics for hemostatics: what drives uptake despite patent barriers?
Answer: Uptake is driven by procurement economics, clinical outcomes (hemostasis speed, reduced re-bleeding), and workflow integration with surgical teams. Even with patent barriers, brands retain share through:
- hospital formulary adoption,
- contracting and volume rebates,
- and evidence-linked differentiation that payers accept.
Hospital purchasing and formulary behavior
- procurement favors products with predictable performance and low training burden,
- supply reliability and lead times matter in trauma and elective surgical blocks,
- switching costs rise when IFU training and stocking practices exist.
Key data table: exclusivity and patent-thicket drivers by hemostatic product modality
| Hemostatic modality | Typical protected claim clusters | Common exclusivity extension levers | Generic/biosimilar entry friction |
|---|---|---|---|
| Thrombin/fibrin sealants | composition ratios, stabilization, delivery format, method-of-use | continuations on concentration/range, process and characterization | high, because formulation + workflow overlap |
| Oxidized polysaccharides | polymer chemistry (oxidation level), absorbability, dwell mechanics, application method | dependent range expansions and sustained-performance claims | medium-high; design-around possible but performance must match |
| Collagen/gelatin matrices | source, crosslinking, particle size distribution, matrix rehydration | formulation and sterilization families | medium; formulation matching required |
| Plasma-derived or recombinant proteins | manufacturing process, potency/characterization, formulation | process and QC acceptance tests | high; biosimilarity and process control constrain substitutes |
| Systemic hemostatic supports (within broader class) | dosing, route, indication, combination protocols | regimen-specific continuations | medium; label/infringement on method-of-use matters |
Key Takeaways
- Hemostatics patent estates are dominated by formulation plus method-of-use coverage, not only by active ingredient composition.
- Exclusivity timing and “effective launch windows” are usually set by the last enforceable patent family covering both the product and its labeled application workflow.
- Generic entry risk is highest where method-of-use claims track labeled IFU steps, since redesigning use instructions can become necessary to avoid infringement.
- Biosimilar risk applies to biologic hemostats through manufacturing-process and characterization patent estates, not just protein sequence similarity.
- Market dynamics remain supportive of incumbents because hemostatics compete on surgical workflow fit and predictable hemostasis performance, increasing switching friction even under patent pressure.
FAQs
- How do method-of-use claims in topical hemostats affect FDA labeling and generic design-around?
- What parts of oxidized polysaccharide hemostatic formulations most often trigger infringement disputes?
- How does settlement language in hemostatic patent cases typically restrict launch timing or indication?
- Do biosimilar developers face more process-related patent risk in biologic hemostats than in other biologics?
- What procurement and formulary levers reduce the ability of generics to gain market share for hemostatics after launch?
References (APA)
- National Library of Medicine. (n.d.). MeSH: Hemostatics. https://www.ncbi.nlm.nih.gov/mesh/
- FDA. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
More… ↓
